Protagenic: Nasdaq non-compliance for late 10-Q; auditor changed; PT00114 Phase I dosing complete

Protagenic Therapeutics, Inc.new

Dismissed MaloneBailey as auditor, engaged Green Growth CPAs as new independent auditor effective August 7, 2025.
Received Nasdaq deficiency notice on Aug 20, 2025 due to late filing of Q2 2025 Form 10-Q; trading continues under PTIX.
Expects to file overdue 10-Q soon; will submit compliance plan within 60 days if needed.
Completed first dose injection for all subjects in multiple-dose portion of Phase I trial of PT00114; topline safety data expected by end of September.

item 3.01item 4.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.